BRPI0308103B8 - vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura - Google Patents
vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufaturaInfo
- Publication number
- BRPI0308103B8 BRPI0308103B8 BRPI0308103A BR0308103A BRPI0308103B8 BR PI0308103 B8 BRPI0308103 B8 BR PI0308103B8 BR PI0308103 A BRPI0308103 A BR PI0308103A BR 0308103 A BR0308103 A BR 0308103A BR PI0308103 B8 BRPI0308103 B8 BR PI0308103B8
- Authority
- BR
- Brazil
- Prior art keywords
- dna
- vegf receptor
- dna vaccine
- endothelial cells
- receptor protein
- Prior art date
Links
- 108010041986 DNA Vaccines Proteins 0.000 title abstract 4
- 229940021995 DNA vaccine Drugs 0.000 title abstract 4
- 210000002889 endothelial cell Anatomy 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 239000003937 drug carrier Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 abstract 3
- 101150030763 Vegfa gene Proteins 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000003527 anti-angiogenesis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- -1 seq. id. nr: 4) Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"vacina de dna contra células endoteliais proliferantes e métodos de uso desta". uma vacina de dna eficaz para inibição de proliferação de célula endotelial que compreende uma construção de dna que codifica operacionalmente uma proteína de receptor de fator de crescimento vascular endotelial (vegf). essa invenção fornece vacinas de dna que codificam receptor-2 de vegf (kdr, id. de seq. nr: 2), receptor-1 de vegf (flt-1, id. de seq. nr: 4), ou flk-l (o homólogo murídeo de kdr, id. de seq. nr: 6), seqüências de dna ids. de seq. nrs: 1, 3, e 5 respectivamente, bem como métodos de uso de tal vacina de dna para inibir proliferação de célula vascular endotelial no microambiente do tumor. é obtida anti-angiogênese e subseqüente diminuição do crescimento e disseminação de tumor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/090.183 | 2002-03-02 | ||
| US10/090,183 US7094410B2 (en) | 2002-03-02 | 2002-03-02 | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| PCT/US2003/006256 WO2003073995A2 (en) | 2002-03-02 | 2003-02-28 | Dna vaccine against proliferating endothelial cells and methods of use thereof. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0308103A BR0308103A (pt) | 2005-01-04 |
| BRPI0308103B1 BRPI0308103B1 (pt) | 2019-02-19 |
| BRPI0308103B8 true BRPI0308103B8 (pt) | 2021-05-25 |
Family
ID=27787599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0308103A BRPI0308103B8 (pt) | 2002-03-02 | 2003-02-28 | vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7094410B2 (pt) |
| EP (1) | EP1487482B1 (pt) |
| JP (1) | JP4598401B2 (pt) |
| KR (1) | KR100979898B1 (pt) |
| CN (1) | CN1293917C (pt) |
| AT (1) | ATE528015T1 (pt) |
| AU (1) | AU2003228229B2 (pt) |
| BR (1) | BRPI0308103B8 (pt) |
| CA (1) | CA2477406C (pt) |
| CY (1) | CY1112663T1 (pt) |
| DK (1) | DK1487482T3 (pt) |
| ES (1) | ES2371870T3 (pt) |
| MX (1) | MXPA04008468A (pt) |
| PL (1) | PL213364B1 (pt) |
| PT (1) | PT1487482E (pt) |
| RU (1) | RU2318019C2 (pt) |
| SI (1) | SI1487482T1 (pt) |
| WO (1) | WO2003073995A2 (pt) |
| ZA (1) | ZA200406988B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1595548A3 (en) * | 2001-03-07 | 2006-02-22 | Mannkind Corporation | Anti-neovasculature preparations for treating cancer |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| KR100614220B1 (ko) | 2004-11-08 | 2006-08-21 | 고려대학교 산학협력단 | Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물 |
| CN101766818B (zh) * | 2008-12-30 | 2013-05-22 | 陕西北美基因股份有限公司 | 多糖金磁复合微粒载药体及其制备方法 |
| JP5539411B2 (ja) * | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
| US9492523B2 (en) | 2011-12-09 | 2016-11-15 | The Board Of Regents For Oklahoma State University | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| ES2650269T3 (es) * | 2011-12-22 | 2018-01-17 | Vaximm Ag | Método para producir cepas atenuadas de salmonela de alto rendimiento |
| CN104519908B (zh) | 2012-07-05 | 2020-10-30 | 万科斯蒙股份有限公司 | 用于胰腺癌患者的dna疫苗 |
| WO2014034735A1 (ja) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Ｖｅｇｆ及び／又はアンギオポエチン－２の特異的エピトープを含むｄｎａワクチン |
| US10548962B2 (en) | 2012-10-22 | 2020-02-04 | The Board Of Regents For Oklahoma State University | Use of the salmonella SPP type III secretion proteins as a protective vaccination |
| US9950053B2 (en) | 2012-10-22 | 2018-04-24 | The Board Of Regents For Oklahoma State University | Use of the Salmonella SPP type III secretion proteins as a protective vaccination |
| US20180153976A1 (en) | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
| JP6947649B2 (ja) | 2015-06-18 | 2021-10-13 | バクシム アクチェンゲゼルシャフト | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
| RU2759227C2 (ru) * | 2020-04-10 | 2021-11-11 | Генетик Диагностикс Энд Терапи 21 Лтд | ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| CA2310252A1 (en) * | 1998-03-06 | 1999-09-10 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
| WO2000014244A2 (en) * | 1998-09-04 | 2000-03-16 | Connaught Laboratories Limited | Treatment of cervical cancer |
| AU2001271976A1 (en) * | 2000-07-07 | 2002-01-21 | Corixa Corporation | Microspheres and adjuvants for dna vaccine delivery |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
-
2002
- 2002-03-02 US US10/090,183 patent/US7094410B2/en not_active Expired - Lifetime
-
2003
- 2003-02-28 EP EP03726007A patent/EP1487482B1/en not_active Expired - Lifetime
- 2003-02-28 PL PL372314A patent/PL213364B1/pl unknown
- 2003-02-28 MX MXPA04008468A patent/MXPA04008468A/es active IP Right Grant
- 2003-02-28 KR KR1020047013668A patent/KR100979898B1/ko active IP Right Grant
- 2003-02-28 RU RU2004129332/13A patent/RU2318019C2/ru active
- 2003-02-28 SI SI200332080T patent/SI1487482T1/sl unknown
- 2003-02-28 PT PT03726007T patent/PT1487482E/pt unknown
- 2003-02-28 CA CA2477406A patent/CA2477406C/en not_active Expired - Lifetime
- 2003-02-28 BR BRPI0308103A patent/BRPI0308103B8/pt not_active IP Right Cessation
- 2003-02-28 CN CNB038099470A patent/CN1293917C/zh not_active Expired - Lifetime
- 2003-02-28 DK DK03726007.2T patent/DK1487482T3/da active
- 2003-02-28 WO PCT/US2003/006256 patent/WO2003073995A2/en active Application Filing
- 2003-02-28 JP JP2003572517A patent/JP4598401B2/ja not_active Expired - Lifetime
- 2003-02-28 AU AU2003228229A patent/AU2003228229B2/en not_active Expired
- 2003-02-28 ES ES03726007T patent/ES2371870T3/es not_active Expired - Lifetime
- 2003-02-28 AT AT03726007T patent/ATE528015T1/de active
-
2004
- 2004-09-01 ZA ZA2004/06988A patent/ZA200406988B/en unknown
-
2006
- 2006-08-21 US US11/507,298 patent/US8048428B2/en active Active
-
2011
- 2011-10-25 US US13/280,855 patent/US8241637B2/en not_active Expired - Lifetime
- 2011-12-20 CY CY20111101264T patent/CY1112663T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0308103B8 (pt) | vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura | |
| AU2020203352B2 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| Tse et al. | mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response | |
| Kowalczyk et al. | Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity | |
| Inderberg et al. | T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth | |
| Chen et al. | T-cell immunity to the joining region of p210BCR-ABL protein. | |
| Rothenfusser et al. | CpG-A and CpG-B oligonucleotides differentially enhance human peptide–specific primary and memory CD8+ T-cell responses in vitro | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| ES2251610T3 (es) | Mutantes de interleuquina-18, su produccion y su uso. | |
| CN109310746A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| Nimanong et al. | CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations | |
| KR101300905B1 (ko) | 백신으로서의 생물학적 활성제와 재조합 마이코박테리움의 조합물 | |
| ES2375053T3 (es) | Péptido derivado de la interleucina-1-beta y su aplicación terapéutica. | |
| Kim et al. | Analyses of the gene structure and function of olive flounder (Paralichthys olivaceus) interleukin 12 (IL-12) | |
| Chakrabarti et al. | Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA) | |
| ES2316638T3 (es) | Ligandos de tnf quimerico. | |
| CA2691406C (en) | Preprocalcitonin antigen t epitopes | |
| Cen et al. | Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RAR α and hIL-2 genes | |
| Azad et al. | Glioblastoma antigen discovery—foundations for immunotherapy | |
| Loria-Cervera et al. | Cloning and sequence analysis of Peromyscus yucatanicus (Rodentia) Th1 (IL-12p35, IFN-γ and TNF) and Th2 (IL-4, IL-10 and TGF-β) cytokines | |
| CN101302524A (zh) | 弓形虫多表位基因与霍乱毒素ctxa2/b亚基的融合基因及应用 | |
| CN102584943A (zh) | 一种血管平滑肌l型钙离子通道免疫原性肽段及其用途 | |
| CN100586476C (zh) | 一种Myostatin特异性抗体的治疗性疫苗及其制备方法 | |
| CN105906705A (zh) | 一种cd19免疫原多肽及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 28/02/2023 |